Core Insights - Jade Biosciences has initiated a Phase 1 clinical trial for JADE101, a monoclonal antibody targeting APRIL for the treatment of immunoglobulin A nephropathy (IgAN) [1][2] - The company anticipates interim clinical data in the first half of 2026, which will provide insights into dosing and biomarker responses [2][6] Company Overview - Jade Biosciences is a clinical-stage biotechnology firm focused on developing therapies for autoimmune diseases, with JADE101 as its lead candidate [4] - The company also has a second candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, in preclinical development [4] Product Details - JADE101 is designed to selectively inhibit APRIL with ultra-high binding affinity and has shown sustained IgA suppression in preclinical studies [3][6] - The drug has a serum half-life of approximately 27 days, allowing for potentially infrequent subcutaneous dosing, which is beneficial for lifelong treatment [3][6] Clinical Trial Information - The Phase 1 trial is randomized, double-blind, and placebo-controlled, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of JADE101 [2][6] - The trial will evaluate single ascending subcutaneous doses in healthy adult volunteers [2][6]